GlassScriptPhysician profile
Don P Allred
NPI 1174510044
$5,036.17
in general payments reported to CMS, 2019-2025
42 companies · $843 in 2025
The $843 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $381 · 2020: $406 · 2021: $764 · 2022: $1,060 · 2023: $810 · 2024: $773 · 2025: $843.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,424.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,198.80 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $415.76 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Glaxosmithkline, LLC. | $407.84 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Astrazeneca Pharmaceuticals LP | $334.81 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $260.65 | 2019-2024 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $218.04 | 2020-2025 | Gardasil 9, Capvaxive, M-M-R II |
| Pfizer INC. | $210.34 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $178.21 | 2019-2023 | |
| Phathom Pharmaceuticals, INC. | $160.30 | 2024-2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $155.67 | 2019-2025 | Spravato |
| Smith+Nephew, INC. | $151.33 | 2022 | |
| Amgen INC. | $107.85 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $89.14 | 2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $81.50 | 2020-2022 | |
| Abbott Laboratories | $77.44 | 2022-2025 | Freestyle Libre 3, Id Now Instrument |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Don Allred listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.